What Is Novo Nordisk A/S (NVO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Novo Nordisk A/S's intrinsic value is estimated at a composite $64.28, showing conflicting signals at the current price of $49.28. While the average implied return is +30.4%, model disagreement is elevated with a gap of +392.1% between the most bullish and bearish estimates. The most optimistic model, Markov DDM, places fair value at $202.49 (+310.9%), while Sentiment SOTP — the most conservative — estimates $9.28 (-81.2%). This +392.1% gap reflects genuine analytical uncertainty about Novo Nordisk A/S's intrinsic worth.
What Do the Models Say About NVO?
12 of 13 models are currently active for NVO. Of these, 6 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates NVO's intrinsic value at $79.60, implying +61.5% upside from the current price. See which stocks rank higher →
How Does NVO Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, NVO ranks #4 by Quality of Company score. CirclFi's QOC score of 10.0/10 evaluates 32 fundamental signals. A score of 10.0 places NVO in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Novo Nordisk A/S competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is NVO a Value Trap?
CirclFi's Value Trap algorithm assigns NVO a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Novo Nordisk A/S. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Novo Nordisk A/S's fundamental quality profile registers 10.0/10. This exceptional score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +392.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every NVO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across NVO's 12 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad